Blockchain Registration Transaction Record

GeoVax Vaccine Shows Full Omicron Protection via T-Cells, Not Antibodies

GeoVax's COVID-19 vaccine candidate shows full Omicron protection in animal models through T-cell immunity, not antibodies. Study published in Frontiers in Immunology demonstrates breakthrough for immunocompromised patients.

This research fundamentally shifts our understanding of COVID-19 immunity by demonstrating that T-cell responses, not just antibodies, can provide complete protection against variants like Omicron. For the approximately 40 million immunocompromised Americans who often don't generate adequate antibody responses to current vaccines, this offers hope for effective protection. The findings suggest that next-generation vaccines targeting multiple viral proteins could provide more durable, variant-resistant immunity for everyone, potentially reducing the need for frequent booster shots and offering better protection as the virus continues to evolve. This represents a significant advancement toward more robust, inclusive pandemic preparedness.